logo
New study to look at impact of food allergies in Singapore children, as cases rise

New study to look at impact of food allergies in Singapore children, as cases rise

Straits Times26-06-2025
Ms Izlin Ismail with her husband Mohamed Huzaini and their 13-year-old son Hayden Anash. Ms Izlin and Hayden are participating in the story. ST PHOTO: SHINTARO TAY
New study to look at impact of food allergies in Singapore children, as cases rise
SINGAPORE – A new four-year study will examine how common food allergies are in children here, as well as the impact of these allergies on children's nutrition, growth, metabolic and mental health.
Led by the National University Hospital (NUH) and the KK Women's and Children's Hospital (KKH), the study was launched in response to a rising number of such cases locally.
KKH has seen a steady rise in the number of patients visiting the hospital's allergy clinics in recent years, said Dr Chong Kok Wee, the study's co-investigator and head of the allergy service at KKH's paediatric medicine department.
'Between 2012 and 2022, the number of children who have tested positive for common food allergies such as milk, eggs, peanuts and shellfish has risen threefold,' added Dr Chong.
Allergies to eggs, milk, and peanuts are more common in younger children, while teens and young adults tend to report shellfish allergies.
Emergency visits for food-related anaphylaxis in children have shot up 2½ times between 2015 and 2022, Dr Chong noted. Anaphylaxis can result in difficulty breathing and a severe drop in blood pressure, and can be fatal.
Other common symptoms range from itchy skin or eczema to swelling of the lips or tongue, as well as difficulty breathing.
Such allergies have typically been thought to be uncommon among Asian populations, said Associate Professor Elizabeth Tham, the study's lead principal investigator.
'However, in our clinical setting, we have been seeing rising numbers of food allergy patients,' said Prof Tham, who heads the paediatric allergy, immunology and rheumatology division at the Khoo Teck Puat – National University Children's Medical Institute at NUH.
NUH said it was unable to provide exact figures on the number of food allergy cases. The Straits Times has asked KKH for its data on such cases.
Both hospitals said they performed 60 per cent more allergy tests between 2022 and 2024. In these tests, known as food challenges, patients are exposed to allergens under clinical supervision to assess whether they are allergic to a specific food.
Prof Tham said the increase in allergies could be due to changes in diet and lifestyle, while Dr Chong pointed to an increased use of antibiotics by children, as well as the hygiene hypothesis – the theory that cleaner environments reduce early exposure to infectious agents, leading to increased susceptibility to allergic diseases – as possible reasons.
A local study conducted between 2011 and 2013 on more than 4,000 children aged between 11 and 30 months found allergy rates of 0.51 per cent for cow's milk and 1.43 per cent for chicken eggs.
However over the past decade the prevalence has not been well-documented, Prof Tham said.
The study will provide an update to existing data on food allergy prevalence, and for the first time, evaluate the impact, as well as the social and economic burden, of food allergies in Singapore, the researchers say.
For instance, Prof Tham noted, a 2013 study in the United States found that the economic impact of food allergies in children amounted to US$24.8 billion ($31.6 billion), of which US$20.5 billion ($21.6 billion) was borne by individual families.
The researchers hope these new insights will bring greater social and infrastructural support for affected children and families.
The study will also involve clinicians and researchers from the National University of Singapore's Yong Loo Lin School of Medicine, National University Polyclinics and the NUS Saw Swee Hock School of Public Health.
It will entail two years of recruitment and two years of data analysis.
The first phase of the study began in February, with a target of surveying at least 2,000 parents and caregivers of children aged between one and two who attend routine developmental and immunisation visits at NUP polyclinics.
They will be asked to complete questionnaires, with those reporting possible allergic reactions to food referred to NUH or KKH for further evaluation.
Of the 549 participants recruited by mid-June, 79 reported a food allergy.
The second phase will begin in July, and will involve about 400 children aged 18 and below, who have been diagnosed with allergies to milk, egg, peanut and shellfish for at least six months.
Participants from the first phase of the study, as well as existing NUH and KKH patients, will be invited to take part in this phase, which will include questionnaires, growth and nutritional assessments, as well as the collection of blood and stool.
Findings from the study will help identify nutrient deficiencies, growth and metabolic abnormalities, in addition to feeding behavioural issues.
These findings will inform future guidelines and educational materials on nutrition, dietary management, as well as mental health support for affected families.
The team is also working with groups such as Singapore Parents of Eczema and Allergy Kids (Speak).
Speak director and creative head Izlin Ismail, 50, and her 13-year-old son Hayden Anash, are participating in the study.
Hayden was three months old when he had to be rushed to the KKH emergency department after experienced swelling of the face and body after drinking a bottle of formula milk. He was later diagnosed with allergies to milk, eggs and peanuts.
Ms Izlin – who is also studio manager at a creative agency – shared that besides Hayden's medical expenses, the family has to spend more on groceries, as allergen-free milk and butter are often more difficult to find and pricier.
Awareness of food allergies has grown over the years, but more can still be done to make matters easier for parents of children with such allergies, she said.
For example, eateries can sometimes see questions about allergens in dishes as patrons being 'fussy'.
'I think restaurants and other places should be able to help us accommodate, and understand when we tell them we have a child with food allergies,' Ms Izlin said.
Join ST's WhatsApp Channel and get the latest news and must-reads.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New programme by Ng Teng Fong General Hospital to tackle allergic rhinitis
New programme by Ng Teng Fong General Hospital to tackle allergic rhinitis

Straits Times

timea day ago

  • Straits Times

New programme by Ng Teng Fong General Hospital to tackle allergic rhinitis

Find out what's new on ST website and app. Ng Teng Fong Hospital ear, nose and throat specialist Ng Chew Lip (left) alongside his patient Ryan Lim, who has spent years managing allergic rhinitis. SINGAPORE - While in Western, often temperate, regions allergic rhinitis tends to be triggered by different allergens based on the seasons – such as pollen in the summer and mould in the winter – in tropical climates the main factor is typically dust mites. The presence of these microscopic insects, which thrive in bedding and upholstery, is why those with the condition tend to have stuffy or runny noses in the morning after waking up, said Adjunct Associate Professor Ng Chew Lip, an ear, nose and throat specialist at Ng Teng Fong General Hospital (NTFGH) . Such differences are one of the reasons for a new initiative, led by the hospital, that aims to improve the diagnosis and long-term management of allergic rhinitis here. Project ENTenna, which began in 2024, hopes to recruit up to 6,000 patients by 2026, with the aim of building a population allergy database for the condition. Data from these patients will be analysed using artificial intelligence to develop personalised treatments and ensure they regularly take their medication, so as to prevent unncessary hospital visits. The programme is supported by the National University Hospital, Tan Tock Seng Hospital (TTSH), Changi General Hospital (CGH) and A*Star. It is funded by the Ministry of Health's Health Innovation Fund and the JurongHealth Fund, a registered charity which supports NTFGH and the Jurong Community Hospital. Top stories Swipe. Select. Stay informed. Singapore Singaporeans aged 21 to 59 can claim $600 SG60 vouchers from July 22 Singapore Singaporeans continue to hold world's most powerful passport in latest ranking Singapore Woman evacuated from lift in Supreme Court building after falling glass triggers emergency halt Asia Malaysian aide's unresolved 2009 death tests govt's reform pledge despite DAP chief's apology Singapore Prosecution says judge who acquitted duo of bribing ex-LTA official had copied defence arguments Singapore Singapore not affected by haze despite smoke plumes in Sumatra: NEA Singapore Miscalculation of MOH subsidies and grants led to $7m in overpayments, $2m in shortfalls Singapore Ports and planes: The 2 Singapore firms helping to keep the world moving Also known as hay fever, allergic rhinitis occurs when a person breathes in particles that they are allergic to, such as pollen, dust mites or mould. Its symptoms are similar to those of the common cold, including uncontrollable sneezing as well as a runny nose with clear mucus. As much as 39 per cent of the population here has allergic rhinitis, said Prof Ng, a senior consultant and the principal investigator for Project ENTenna. How the condition affects Asian populations is also not well documented, he said. For example, there may be genetic differences between Western and Asian populations that influence the impact of allergic rhinitis. This means medication developed in the West may not be as effective in treating allergic rhinitis in Asians, said Prof Ng. 'What we hope for is that as Asia progresses, we develop our own specific patient treatments,' he said. A research collaboration with A*Star's Singapore Immunology Network will see molecular-level investigations undertaken to identify new therapeutic targets – referring to molecules or pathways in the body that can be affected by new treatments – as well as explore why patients experience different responses to the same treatment. The programme uses AI-powered symptom trackers and reminders to improve patients' management of their conditions. Project ENTenna can also manage other conditions such as giddiness and tinnitus, with the data-driven care model being developed possessing the potential to be expanded to other chronic conditions in the future, said the programme's co-principal investigator, Dr Tan Jian Li, a consultant with the otorhinolaryngology department at TTSH. As part of the initiative, a WhatsApp chatbot is being developed that reminds patients to take their medication on time as well as provides travel advice based on real-time updated environmental data, such as the air pollution index. 'By better understanding the varying experiences of patients living with allergic rhinitis through the chatbot, and translating information into actionable insights using the Al model, Project ENTenna can enable clinicians to move towards proactive care strategies and early interventions to enhance patient outcomes,' said CGH health services research department deputy director, Dr Oh Hong Choon. Among the 2,000 patients recruited so far is Singapore Management University student Ryan Lim, who was diagnosed with the condition about four years ago. The 21-year-old said he would often wake up feeling congested and fatigued, with his nostrils blocked for days on end on particularly bad occasions. The questionnaires and reminders he receives as part of the programme help remind him to take his medication, as well as track their effectiveness. 'I was able to better understand if the medicine wasn't really working, and say hey, let's switch to a different spray,' he said.

Trial of new dengue vaccine begins recruitment for child participants in Singapore
Trial of new dengue vaccine begins recruitment for child participants in Singapore

Straits Times

time3 days ago

  • Straits Times

Trial of new dengue vaccine begins recruitment for child participants in Singapore

Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store